Dosing and concentration
The documented adult tirzepatide injection instructions start at 2.5 mg once weekly for four weeks, then 5 mg weekly. Subsequent increases are in 2.5 mg steps after at least four weeks at the current dose, if needed and tolerated; the labelled maximum is 15 mg weekly. The starting amount is for initiation, not an instruction to remain indefinitely or advance automatically.
The same milligram dose can come in different volumes. Current presentations include single-dose and multi-dose products, so a remembered “half a millilitre” rule is unreliable. Read milligrams per dose and milligrams per millilitre separately.
For arithmetic only, a 10 mg/mL solution contains 2.5 mg in 0.25 mL. A U-100 syringe marks that volume as 25 units; tirzepatide itself is prescribed in milligrams, not insulin units. Have the actual concentration and measuring device checked before using a vial. Do not use pen clicks as a substitute for documented dose instructions.
Preparation and reconstitution
Ready-made tirzepatide solutions are already formulated. A vial is not necessarily lyophilised, and a multi-dose vial is not the same as a single-dose vial. Do not add bacteriostatic water to a ready-to-use medicine.
Lyophilised means freeze-dried. To prepare such material correctly, the instructions must specify a compatible diluent, exact liquid volume and final concentration. Bacteriostatic water usually contains benzyl alcohol, which slows growth of some bacteria; it does not make contaminated material sterile or demonstrate that a research preparation is fit for injection.
Keep the compound name, total amount, concentration, route, opening date and discard date together. “Add two mL” without the vial strength is incomplete information. If two people use different vial strengths, identical syringe markings can deliver different doses.
Administration
Injection under the skin places medicine in the fatty layer beneath the skin, commonly at the abdomen, thigh or upper arm according to the presentation's instructions. Rotate sites. Avoid inflamed, bruised or damaged skin, and never inject into a lump simply because it feels less sensitive.
Use clean hands, a clean work area and new sterile equipment. The device determines whether a separate needle is required and how long it should remain in place. Never share pens or syringes. Dispose of used needles in a sharps container rather than placing loose sharps in household rubbish.
Timing relative to meals is not a substitute for consistent weekly records. If medicine leaks or delivery is uncertain, do not immediately repeat the whole dose. Record what happened and obtain product-specific advice.
Oral versus subcutaneous delivery
Subcutaneous tirzepatide bypasses the stomach and intestinal enzymes that break down many peptides. Ordinary oral capsules or drops do not reproduce the exposure of a studied injection. An oral absorption percentage needs evidence for that particular formulation, not a comparison based only on its label strength.
A peptide can sometimes be delivered orally to act locally on gut tissue, but tirzepatide's established clinical use relies on systemic hormone-receptor effects. Reduced oral absorption is not evidence that an unstudied oral preparation will provide a useful local intestinal treatment.
Half-life
Tirzepatide's half-life is approximately five days. Weekly doses overlap, so levels build over several weeks. Side effects may take time to settle after a change; the previous dose is not gone the next morning.
Storage
Refrigeration and room-temperature allowances differ between presentations. The documented single-dose product permits storage at up to 30°C for a total of 21 days. Multi-dose presentations have different opening and discard rules. None of these allowances can be transferred to an unidentified reconstituted vial.
Protect the actual product as directed, avoid freezing and keep a dated record of any temperature excursion. Do not place it directly against an ice pack. A travel pouch can prevent light exposure but cannot prove that its contents remained within temperature limits.
Contraindications and side effects
The documented label contraindicates use with personal or family medullary thyroid carcinoma, MEN2 or serious allergy. Nausea, diarrhoea, vomiting and constipation are common concerns. Persistent severe abdominal pain, dehydration or a serious allergic reaction requires medical assessment.
Tell the clinician about severe stomach-emptying problems, pancreatitis, gallbladder disease and glucose-lowering medicines. Pregnancy and planned pregnancy require review. Oral hormonal contraceptives need particular attention: the label advises a non-oral method or added barrier protection for four weeks after initiation and after each dose escalation.
Inform an anaesthesia team before surgery or deep sedation. Delayed stomach emptying can matter even when usual fasting instructions were followed. Never stop essential oral medicines on your own; discuss whether absorption or timing needs review.
Tracking progress and common questions
Log weekly amount, formulation, dose changes, appetite, bowel symptoms and hydration. Compare weight under similar conditions rather than reacting to every daily fluctuation. Note strength and energy as well as body measurements.
“Does stronger appetite suppression mean I should eat as little as possible?” No: under-eating can produce weakness and nutrient gaps. “Can I change to another peptide at the same milligrams?” No. “Should I take extra because hunger returns before the next dose?” Hunger alone is not a dosing instruction. Review the overall pattern and the current plan with the clinician.